menu
    • menu
    [{"orgOrder":0,"company":"Medicure","sponsor":"SCRI Development Innovations, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tirofiban Hydrochloride Monohydrate","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicure \/ SCRI Development Innovations, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/ SCRI Development Innovations, LLC"},{"orgOrder":0,"company":"Medicure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban Hydrochloride Monohydrate","moa":"||Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicure \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medicure \/ Undisclosed"},{"orgOrder":0,"company":"Medicure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban Hydrochloride Monohydrate","moa":"||Integrin alpha-IIb\/beta-3","graph1":"Hematology","graph2":"Phase II","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicure \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Grand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirofiban Hydrochloride Monohydrate","moa":"Integrin alpha-IIb\/beta-3","graph1":"Neurology","graph2":"Phase IV","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Tiantan Hospital \/ Grand Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Beijing Tiantan Hospital \/ Grand Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Tirofiban Hydrochloride Monohydrate

    Menu

    Tirofiban Hydrochloride Monohydrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Beijing Tiantan Hospital

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Beijing Tiantan Hospital

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Grand Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

                            Details : Tirofiban HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Branch Atheromatous Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 05, 2022

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Grand Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medicure

                            Canada arrow
                            SupplySide West
                            Not Confirmed

                            Medicure

                            Canada arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Aspirin,Clopidogrel

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Cli...

                            Details : Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves...

                            Product Name : Aggrastat

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 24, 2020

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Aspirin,Clopidogrel

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medicure

                            Canada arrow
                            SupplySide West
                            Not Confirmed

                            Medicure

                            Canada arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Prasugrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT

                            Details : The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of prima...

                            Product Name : Aggrastat

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 15, 2020

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Prasugrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medicure

                            Canada arrow
                            SupplySide West
                            Not Confirmed

                            Medicure

                            Canada arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : SCRI Development Innovations, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

                            Details : Aggrastat (Tirofiban HCl) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myocardial Infarction.

                            Product Name : Aggrastat

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2010

                            Lead Product(s) : Tirofiban Hydrochloride Monohydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : SCRI Development Innovations, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth